文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

葡萄糖-6-磷酸脱氢酶缺乏与美国退伍军人COVID-19结局的关联

Association of Glucose-6-Phosphate Dehydrogenase Deficiency With Outcomes in US Veterans With COVID-19.
PubMed 文献 · JAMA Netw Open · 2023-03-01
一句话结论在COVID-19阳性退伍军人中,<65岁黑人男性和≥65岁白人男性G6PD缺乏者发生重症的 likelihood 增加(OR分别为1.47和3.58)。

这项回顾性队列研究分析了4811例SARS-CoV-2检测阳性的美国退伍军人,这些退伍军人此前均有G6PD酶活性检测结果。主要终点为CDC定义的COVID-19重症(住院、需要机械通气或ICU入住、或院内死亡)。在<65岁黑人男性退伍军人中,G6PD缺乏与重症 likelihood 增加相关(OR 1.47; 95% CI 1.03-2.09);在≥65岁白人男性退伍军人中,G6PD缺乏与重症 likelihood 增加相关(OR 3.58; 95% CI 1.64-7.80)。这种差异在年轻白人男性、年长黑人男性、其他男性亚组及任何年龄的女性退伍军人中未观察到。作者认为,在治疗SARS-CoV-2感染患者前应考虑G6PD缺乏的可能性,作为减轻重症结局的临床策略的一部分。

要点

  • <65岁黑人男性退伍军人中,G6PD缺乏者较无缺乏者发生COVID-19重症的 likelihood 增加(OR 1.47; 95% CI 1.03-2.09)。
  • ≥65岁白人男性退伍军人中,G6PD缺乏者较无缺乏者发生COVID-19重症的 likelihood 增加(OR 3.58; 95% CI 1.64-7.80)。
  • 年轻白人男性、年长黑人男性、其他男性亚组及任何年龄的女性退伍军人中未观察到G6PD缺乏与重症的关联。
  • 在SARS-CoV-2感染的退伍军人中,G6PD缺乏在黑人男性退伍军人中更普遍(309/454 [68.1%])。
  • 作者认为,治疗SARS-CoV-2感染患者前应考虑G6PD缺乏的可能性,作为减轻重症结局的临床策略的一部分。

适用人群与场景

  • 美国退伍军人健康管理局 national databases 中截至2020年1月1日有G6PD酶检测结果的24700名退伍军人,与2020年2月15日至2021年1月1日SARS-CoV-2检测数据交叉比对,最终研究人群为4811名SARS-CoV-2检测阳性的退伍军人。
  • 研究人群特征:3868名(80.4%)男性,1553名(32.3%)黑人,1855名(39%)白人;1228名(25.5%)≥65岁,3583名(74.5%)<65岁。
  • G6PD缺乏与无缺乏的退伍军人之间,年龄、体重指数或Charlson合并症指数无显著差异。

诊断标准与关键阈值

  • COVID-19重症定义(美国疾病控制与预防中心):SARS-CoV-2检测阳性后住院、需要机械通气和/或入住重症监护室、或院内死亡。

研究设计与关键结果

  • 研究类型:回顾性队列研究,纳入4811名SARS-CoV-2检测阳性的退伍军人,均有历史G6PD酶活性检测结果。
  • 主要终点为CDC定义的COVID-19重症;<65岁黑人男性退伍军人中,G6PD缺乏者较无缺乏者发生重症的 likelihood 增加(OR 1.47; 95% CI 1.03-2.09)。
  • ≥65岁白人男性退伍军人中,G6PD缺乏者较无缺乏者发生重症的 likelihood 增加(OR 3.58; 95% CI 1.64-7.80)。
  • 年轻白人男性退伍军人、年长黑人男性退伍军人、其他男性退伍军人较小亚组及任何年龄的女性退伍军人中,未观察到G6PD缺乏与无缺乏者之间的差异。
  • 在SARS-CoV-2感染的退伍军人中,G6PD缺乏在黑人男性退伍军人中更普遍(309/454 [68.1%]),与其他种族和族裔群体相比。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,这些数据表明在治疗SARS-CoV-2感染患者前需要考虑G6PD缺乏的可能性,作为减轻重症结局的临床策略的一部分。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The underlying biological risk factors for severe outcome due to SAR-CoV-2 infection are not well defined.

OBJECTIVE: To determine the association between glucose-6-phosphate dehydrogenase (G6PD) deficiency and severity of COVID-19.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included analysis of 24 700 veterans with G6PD enzyme testing prior to January 1, 2020, obtained through the US Veterans Health Administration national databases. These veterans were cross-referenced with the Veterans Administration COVID-19 Shared Data Resource for SARS-CoV-2 testing from February 15, 2020, to January 1, 2021. The final study population consisted of 4811 veterans who tested positive for SARS-CoV-2. Statistical analysis was performed from June to December 2021.

EXPOSURES: G6PD deficiency.

MAIN OUTCOMES AND MEASURES: COVID-19 severe illness, as defined by the Centers for Disease Control and Prevention: hospitalization, need for mechanical ventilation and/or intensive care unit admission, or in-hospital mortality after a positive SARS-CoV-2 test.

RESULTS: Among 4811 veterans in the Veterans Health Administration who had historical G6PD enzyme activity test results and SARS-CoV-2 positivity included in this study, 3868 (80.4%) were male, 1553 (32.3%) were Black, and 1855 (39%) were White; 1228 (25.5%) were 65 years or older and 3583 (74.5%) were younger than 65 years. There were no significant differences in age, body mass index, or Charlson Comorbidity Index were present between the veterans with G6PD deficiency and without G6PD deficiency. Among these veterans with SARS-CoV-2 infection, G6PD deficiency was more prevalent in Black male veterans (309 of 454 [68.1%]) compared with other racial and ethnic groups. Black male veterans less than 65 years of age with G6PD deficiency had approximately 1.5-fold increased likelihood of developing severe outcomes from SARS-CoV-2 infection compared with Black male veterans without G6PD deficiency (OR, 1.47; 95% CI, 1.03-2.09). In the small subset of White male veterans with G6PD deficiency, we observed an approximately 3.6-fold increased likelihood of developing severe outcomes from SARS-CoV-2 infection compared with White male veterans aged 65 years or older without G6PD deficiency (OR, 3.58; 95% CI, 1.64-7.80). This difference between veterans with and without G6PD deficiency was not observed in younger White male veterans or older Black male veterans, nor in smaller subsets of other male veterans or in female veterans of any age.

CONCLUSIONS AND RELEVANCE: In this cohort study of COVID-19-positive veterans, Black male veterans less than 65 years of age and White male veterans 65 years of age or older with G6PD deficiency had an increased likelihood of developing severe COVID-19 compared with veterans without G6PD deficiency. These data indicate a need to consider the potential for G6PD deficiency prior to treatment of patients with SARS-CoV-2 infection as part of clinical strategies to mitigate severe outcomes.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Elsea SH, Razjouyan J, Lee KM, et al. Association of Glucose-6-Phosphate Dehydrogenase Deficiency With Outcomes in US Veterans With COVID-19. JAMA Netw Open. 2023. PMID: 36988953. doi:10.1001/jamanetworkopen.2023.5626

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。